Inclusion Criteria:

- Histologically-confirmed diagnosis of invasive breast cancer

- Clinical stage T2, N0 or N1, M0 (TNM Classification)

- Patients must be postmenopausal

- Tumors are estrogen receptor (ER) positive and human epidermal growth factor receptor
(HER2) negative

- ECOG Performance status (PS) 0 or 1

- Patients must be able to swallow tablets and capsules

- Candidates for mastectomy or breast-conserving surgery

- Adequate bone marrow, liver and renal function

- Written informed consent was obtained from all patients before randomization.

Exclusion Criteria:

- Inoperable, bilateral or inflammatory breast cancer

- multiple carcinoma

- Personal history of invasive carcinoma

- Patients receive systemic therapy of corticosteroid

- Patients receive estrogen preparation or raloxifene

- Patients with other concurrent severe and/or uncontrolled medical disease

- Patients whom doctors judged inadequate to the enrollment of this study by other
reasons.